孟鲁司特对哮喘患儿治疗效果的影响因素研究  

Research on the factors related to heterogeneity of response to montelukast in children with asthma

作　　者：王兰兰(综述)[1] 王晓明(审校)[1] 

机构地区：[1]复旦大学附属上海市第五人民医院儿科,200240

出　　处：《国际儿科学杂志》2014年第2期124-127,共4页International Journal of Pediatrics

摘　　要：随着白三烯受体拮抗剂孟鲁司特在儿童支气管哮喘治疗中的应用,其药物疗效的个体差异及相关影响因素备受关注.目前此方面的研究虽取得了一定进展,但尚处于开展阶段,已有的研究结果仍存在颇多争议.该文主要对影响孟鲁司特疗效的相关因素,包括患儿个体特征、体重指数、吸烟环境暴露及遗传变异等进行综述,旨在对孟鲁司特用药的选择提供相关参考因素,促进药物治疗个体化,提高药物疗效,达到哮喘理想控制.As the application of leukotriene receptor antagonists （LTRA） is widely used among children with asthma,the heterogeneity of response to montelukast and its related factors are attracting more and more attention.At present,the research has made some progresses,but it is still in the stage of development and cannot reach a consensus.The related factors,including individual characteristics,body mass index,smoking exposure,genetic factors are described in this review,to improve the rationality of drug selection in order to reduce side effects 、improving therapeutic efficacy and achieve good asthma control.

关 键 词：白三烯受体拮抗剂 哮喘 治疗效果 儿童 

分 类 号：R562.25[医药卫生—呼吸系统]